Anna Shteingauz

1.3k total citations
40 papers, 969 citations indexed

About

Anna Shteingauz is a scholar working on Biomedical Engineering, Molecular Biology and Cell Biology. According to data from OpenAlex, Anna Shteingauz has authored 40 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Biomedical Engineering, 19 papers in Molecular Biology and 10 papers in Cell Biology. Recurrent topics in Anna Shteingauz's work include 3D Printing in Biomedical Research (12 papers), Autophagy in Disease and Therapy (9 papers) and Nanoplatforms for cancer theranostics (9 papers). Anna Shteingauz is often cited by papers focused on 3D Printing in Biomedical Research (12 papers), Autophagy in Disease and Therapy (9 papers) and Nanoplatforms for cancer theranostics (9 papers). Anna Shteingauz collaborates with scholars based in Israel, United States and Switzerland. Anna Shteingauz's co-authors include Moshe Giladi, Yoram Palti, Mijal Munster, Tali Voloshin, Uri Weinberg, Israël Vlodavsky, Rosa S. Schneiderman, Eilon D. Kirson, Neta Ilan and Yaara Porat and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anna Shteingauz

38 papers receiving 941 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Shteingauz Israel	13	415	288	282	261	147	40	969
Mijal Munster United States	12	238 0.6×	414 1.4×	78 0.3×	338 1.3×	158 1.1×	51	878
Rupavathana Mahesparan Norway	14	414 1.0×	278 1.0×	220 0.8×	148 0.6×	164 1.1×	33	1.1k
Tali Voloshin Israel	19	490 1.2×	495 1.7×	111 0.4×	441 1.7×	404 2.7×	79	1.4k
Thomas Daubon France	21	696 1.7×	238 0.8×	393 1.4×	120 0.5×	278 1.9×	54	1.3k
Tamra E. Werbowetski‐Ogilvie Canada	20	1.2k 2.8×	271 0.9×	255 0.9×	309 1.2×	367 2.5×	34	1.7k
Mika Pietilä Finland	17	507 1.2×	290 1.0×	112 0.4×	102 0.4×	278 1.9×	24	1.1k
Uri Weinberg Switzerland	18	494 1.2×	724 2.5×	115 0.4×	676 2.6×	311 2.1×	114	1.8k
Roni Blat Switzerland	7	155 0.4×	295 1.0×	54 0.2×	217 0.8×	110 0.7×	21	580
Shay Cahal United States	7	166 0.4×	266 0.9×	53 0.2×	276 1.1×	116 0.8×	22	640
Guénaëlle Levallet France	18	494 1.2×	167 0.6×	191 0.7×	57 0.2×	173 1.2×	54	985

Countries citing papers authored by Anna Shteingauz

Since Specialization

Citations

This map shows the geographic impact of Anna Shteingauz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Shteingauz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Shteingauz more than expected).

Fields of papers citing papers by Anna Shteingauz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Shteingauz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Shteingauz. The network helps show where Anna Shteingauz may publish in the future.

Co-authorship network of co-authors of Anna Shteingauz

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Shteingauz. A scholar is included among the top collaborators of Anna Shteingauz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Shteingauz. Anna Shteingauz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Shteingauz, Anna, Catherine Tempel-Brami, Einav Zeevi, et al.. (2022). Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo.. Journal of Clinical Oncology. 40(4_suppl). 464–464. 1 indexed citations

2.

Shteingauz, Anna, Catherine Tempel-Brami, Einav Zeevi, et al.. (2022). Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers. 14(12). 2959–2959. 21 indexed citations

3.

Blatt, Roni, Mijal Munster, Anna Shteingauz, et al.. (2021). In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso. Frontiers in Oncology. 11. 670809–670809. 20 indexed citations

4.

Voloshin, Tali, Noa Kaynan, Yaara Porat, et al.. (2020). Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology Immunotherapy. 69(7). 1191–1204. 114 indexed citations

5.

Voloshin, Tali, Noa Kaynan, Yaara Porat, et al.. (2020). Immunomodulatory effects of tumor treating fields (TTFields) on colon cancer models.. Journal of Clinical Oncology. 38(4_suppl). 136–136. 1 indexed citations

6.

Munster, Mijal, Rosa S. Schneiderman, Yaara Porat, et al.. (2019). Abstract 307: The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and Cisplatin or Pemetrexed inhibit mesothelioma cells in vitro. Cancer Research. 79(13_Supplement). 307–307. 1 indexed citations

7.

Zeevi, Einav, Rosa S. Schneiderman, Mijal Munster, et al.. (2019). The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and FOLFOX Inhibit Gastric Cancer in Vitro. International Journal of Radiation Oncology*Biology*Physics. 105(1). E681–E681. 1 indexed citations

8.

Weinberg, Uri, Noa Kaynan, Yaara Porat, et al.. (2019). Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models. Annals of Oncology. 30. ii2–ii3. 5 indexed citations

9.

Munster, Mijal, Rosa S. Schneiderman, Yaara Porat, et al.. (2019). Efficacy of Tumor Treating Fields (TTFields) in Combination with Cisplatin or Pemetrexed for the Treatment of Mesothelioma in Vitro and in Vivo. International Journal of Radiation Oncology*Biology*Physics. 105(1). E679–E679. 1 indexed citations

10.

Shteingauz, Anna, Yaara Porat, Tali Voloshin, et al.. (2018). AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death and Disease. 9(11). 1074–1074. 82 indexed citations

11.

Schneiderman, Rosa S., Moshe Giladi, Einav Zeevi, et al.. (2018). ANGI-11. TUMOR TREATING FIELDS (TTFIELDS) INHIBIT CANCER CELL MIGRATION AND INVASION BY INDUCING REORGANIZATION OF THE ACTIN CYTOSKELETON AND FORMATION OF CELL ADHESIONS. Neuro-Oncology. 20(suppl_6). vi30–vi30. 4 indexed citations

12.

Voloshin, Tali, Yaara Porat, Anna Shteingauz, et al.. (2018). IMMU-52. TUMOR TREATING FIELDS (TTFIELDS) INDUCE IMMUNOGENIC CELL DEATH RESULTING IN ENHANCED ANTITUMOR EFFICACY WHEN COMBINED WITH ANTI-PD-1 THERAPY. Neuro-Oncology. 20(suppl_6). vi133–vi133. 2 indexed citations

13.

Porat, Yaara, Moshe Giladi, Rosa S. Schneiderman, et al.. (2017). Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). Journal of Visualized Experiments. 23 indexed citations

14.

Porat, Yaara, Moshe Giladi, Rosa S. Schneiderman, et al.. (2017). Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). Journal of Visualized Experiments. 46 indexed citations

15.

Weinberg, Uri, Tali Voloshin, Noa Kaynan, et al.. (2017). Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models. Annals of Oncology. 28. ii11–ii12. 1 indexed citations

16.

Porat, Yaara, Anna Shteingauz, Moshe Giladi, et al.. (2016). Abstract 3543: Alternating electric fields (TTFields) induce autophagy in human cancer cell lines. Cancer Research. 76(14_Supplement). 3543–3543. 2 indexed citations

17.

Shteingauz, Anna, Ilanit Boyango, Inna Naroditsky, et al.. (2015). Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Research. 75(18). 3946–3957. 130 indexed citations

18.

Shteingauz, Anna, Neta Ilan, Roman A. Blaheta, et al.. (2015). Latent Heparanase Facilitates VLA-4–Mediated Melanoma Cell Binding and Emerges As a Relevant Target of Heparin in the Interference with Metastatic Progression. Seminars in Thrombosis and Hemostasis. 41(2). 244–254. 9 indexed citations

19.

Shteingauz, Anna, Neta Ilan, & Israël Vlodavsky. (2014). Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin. Cellular and Molecular Life Sciences. 71(22). 4457–4470. 31 indexed citations

20.

Levy‐Adam, Flonia, Sari Feld, Victoria Cohen‐Kaplan, et al.. (2010). Heparanase 2 Interacts with Heparan Sulfate with High Affinity and Inhibits Heparanase Activity. Journal of Biological Chemistry. 285(36). 28010–28019. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact